P401 RAPID ONSET OF ACTION OF A NOVEL BUDESONIDE NASAL SPRAY IN GRASS POLLEN ALLERGIC RHINITIS

2019 ◽  
Vol 123 (5) ◽  
pp. S57
Author(s):  
P. Zieglmayer ◽  
P. Lemell ◽  
N. Unger- Manhart ◽  
A. Goessl ◽  
R. Zieglmayer ◽  
...  
1993 ◽  
Vol 21 (5) ◽  
pp. 268-275 ◽  
Author(s):  
R Gambardella

A total of 30 patients suffering from seasonal allergic rhinitis were treated in a 6-week randomized, double-blind, double-dummy parallel-group study, comparing azelastine nasal spray (0.14 mg/nostril administered twice daily) and loratidine tablets (10 mg once daily). Symptoms evaluated were sneezing, nose and/or eye itching, lacrimation, rhinorrhoea, photophobia, nasal occlusion, throat irritation, smell loss, nasal mucosa swelling, conjunctivitis, and pharyngeal mucosa reddening. Each symptom was assessed according to severity and given a score on a fourpoint rating scale. Compared with baseline, total symptom scores for both the azelastine and loratidine treatment groups were reduced at each of the assessments during treatment. No significant differences were observed between the two treatment groups. The investigator concluded that azelastine, formulated as a nasal spray, is as effective as loratidine tablets in the relief of the symptoms of seasonal rhinitis and that it has a rapid onset of action. Un gruppo di 30 pazienti affetti da rinite allergica stagionale è stato trattato, in uno studio radomizzato, tra gruppi paralleli, doppio cieco, double dummy della durata di 6 settimane con azelastina spray nasale (0.14 mg/narice 2 volte al giorno) e loratina compresse (10 mg/die). I sintomi controllati sono stati i seguenti: starnuti, prurito nasale e/o oculare, lacrimazione, rinorrea, fotofobia, occlusione nasale, irritazione faringea, perdita dell'olfatto, edema della mucosa nasale, congiuntivite ed arrossamento della mucosa faringea. I sintomi sono stati valutati in base alia loro gravità assegnando un punteggio variabile da 1 a 4. In entrambi i gruppi di trattamento il punteggio totale della sintomatologia è risultato inferiore a quello basale ad ogni controllo nel corso dei trattamenti. Non sono state rilevate differenze significative tra i due trattamenti che si sono dimostrati entrambi efficaci. I ricercatori hanno concluso che azelastina spray nasale ha la stessa efficacia di loratidina compresse nell'alleviare i sintomi della rinite allergica stagionale e possiede una notevole rapidità di azione ed una notevole maneggevolezza clinica.


Allergy ◽  
1999 ◽  
Vol 54 (1) ◽  
pp. 64-69 ◽  
Author(s):  
Rb Berkowitz ◽  
Di Bernstein ◽  
C LaForce ◽  
Aj Pedinoff ◽  
Ar Rooklin ◽  
...  

2002 ◽  
Vol 89 (3) ◽  
pp. 279-284 ◽  
Author(s):  
Wytske J. Fokkens ◽  
Endre Cserháti ◽  
José Manuel Lopes Santos ◽  
Fatima Praca ◽  
Marinus van Zanten ◽  
...  

2011 ◽  
Vol 60 (05) ◽  
pp. 249-255
Author(s):  
Horak Friedrich ◽  
Zieglmayer Petra ◽  
Zieglmayer René ◽  
Lemell Patrick

2013 ◽  
Vol 10 (1) ◽  
pp. 63-77
Author(s):  
I S Gushchin

Rupatadine is a new poly-functional agent (selective histamine H 1-receptor and PAF-receptor antagonist with additional anti-inflammatory potency) for the management of patients with allergic rhinitis and chronic urticaria. It has a rapid onset of action, and its long-lasting effect permits once-daily dosing. It has been shown that rupatadine is effective, well-tolerated and safe in relieving symptoms in patients with seasonal and perennial/ intermittent and persistent allergic rhinitis and chronic urticaria.


1995 ◽  
Vol 4 (7) ◽  
pp. S11-S15 ◽  
Author(s):  
Ralph Mösges ◽  
Joachim Spaeth ◽  
Ludger Klimek

Levocabastine and azelastine are currently the only antihistamines available as nasal sprays for the topical therapy of seasonal allergic rhinitis. The present study was undertaken to compare the onset of action, efficacy and tolerability of these two agents in a total of 242 patients with this condition. This was an international, multicentre, open-label, randomized, parallel-group trial with 123 patients treated with levocabastine (0.5 mg/ml, two puffs per nostril twice daily) and 119 with azelastine (1 mg/ml, one puff per nostril twice daily). Onset of action was comparable for the two drugs with over 50% of patients in each group reporting significant symptomatic relief within 30 min of administration of the first dose of study medication. Therapeutic efficacy was also found to be comparable in the two groups with no statistically significant intergroup differences reported for any of the parameters evaluated, although assessments of global therapeutic efficacy revealed a trend favouring levocabastine. Levocabastine appeared to be better tolerated than azelastine (p = 0.06), with the incidence of the most common adverse experiences, application site reactions and taste disturbances, significantly higher on azelastine than with levocabastine (5% versus 1%; p = 0.05 and 5% versus 0%; p = 0.01, respectively). In conclusion, levocabastine nasal spray appears to be at least as effective as, but better tolerated than, azelastine nasal spray for the treatment of seasonal allergic rhinitis.


Sign in / Sign up

Export Citation Format

Share Document